Diet Induced Obesity Model for Cancer Research
A More Clinically Relevant Model to Uncover Your Treatment’s Potential
Obesity is a risk factor for at least 13 different forms of cancer. Mechanisms in which obesity and changes in systemic metabolism affect the tumor microenvironment (TME) and impact antitumor immunity are unclear. Current preclinical models use mouse strains which are fed a controlled diet and therefore host mice are not representative of Western human cancer populations. TD2 has established a diet induced obesity tumor model (Figure 1) to screen cancer therapies in a more clinically relevant system.
TD2 integrates the use of syngeneic tumor models with the DIO mouse model to enhance the clinical relevance of preclinical, immune checkpoint inhibitor in vivo studies. This innovative approach allows for the evaluation of cancer therapies within an obese phenotype, which closely mirrors the metabolic and immune conditions present in a significant portion of the cancer patient population. By utilizing syngeneic tumor models in DIO mice, TD2 provides a comprehensive platform that captures the complex interplay between tumor growth, obesity, and the immune system. This platform is particularly important for understanding how obesity alters the tumor microenvironment and affects the efficacy of cancer treatments, including immunotherapies.
Figure 1: Establishment of diet induced obesity mouse tumor model
Benefits of Diet Induced Obesity Mouse Models:
- Execute studies in more clinically relevant models reflective of the significant rates of obesity projected by 2035.
- Understand how obesity induced systemic changes in metabolism effect the tumor microenvironment
- Identify new treatments/mechanism of action that may show increased therapeutic benefit in DIO models
- Quantify metabolite and proteomic changes in response to treatment that could be used as biomarkers of treatment benefit or as opportunity for new targets for drug development